Yesterday, Cue Biopharma (CUE) announced a clinical trial collaboration with pharma giant Merck (MRK) to test CUE-101 in combination with Keytruda.

Shares promptly rallied above $22 on heavy volume, pushing our gains north of 100% since our entry.

Typically, I’d recommend taking some profits off the table at this point. Especially in a biotech that’s supposed to report data before the end of June.

But I’m letting my position ride.

Why? Because shares could ultimately be worth as much as $150.

Here are all the details…


This content is reserved for subscribers. To gain immediate access to our 100% independent research on the top tech trends and companies before they become household names, consider subscribing here.

For a limited time only you can use Coupon Code DTR50 to receive 50% off a quarterly or annual subscription.